Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets

Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target